



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT

LDC24-005: Retail Marijuana Stores and Marijuana Production at DEA-Authorized Facilities



Two Proposed Changes

1. Retail marijuana: allow retail store to relocate within the same building without a public hearing process
2. Allow marijuana product manufacturing within DEA-licensed facilities in industrial zone districts



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT

Cannabis Rescheduling: Record 43,000 Public Comments Submitted To The DEA

Andrew DeAngelo Contributor

I write about cannabis business and culture.

Follow



Aug 12, 2024, 11:41am EDT



Retail Marijuana



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT

- Arapahoe County allows four commercial marijuana stores within the unincorporated area (medical and/or retail)
- Stores may relocate through a use by special review process with a public hearing
- Stores may replace, repair, or expand their premises within the same structure without a use by special review process
- Proposal would also allow *relocation* within the same structures without a public hearing



Retail Marijuana – Fictitious Example



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT



Production in DEA-Registered Facilities



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT

- DEA licenses facilities for both cultivation and production of marijuana-derived products
- Separate program from any individual state medical/retail regulations – no interaction with those markets
- Proposed change would allow DEA registered facilities in industrial zones (I-1, I-2, and PUD areas allowing industrial uses)

May 14, 2021

DEA Continues to Prioritize Efforts to Expand Access to Marijuana for Research in the United States

DEA Headquarters Division - Public Information Office

On May 14, 2021, the Drug Enforcement Administration took an important step to increase opportunities for medical and scientific research. DEA is nearing the end of its review of certain marijuana grower applications, thereby allowing it to soon register additional entities authorized to produce marijuana for research purposes. Currently, the National Center for the Development of Natural Products at the University of Mississippi is the only approved supplier of marijuana for research purposes in the United States, and that production has been exclusively for the National Institute on Drug Abuse.

Pending final approval, DEA has determined, based on currently available information, that a number of manufacturers' applications to cultivate marijuana for research needs in the United States appears to be consistent with applicable legal standards and relevant laws. DEA has, therefore, provided a Memorandum of Agreement (MOA) to these manufacturers as the next step in the approval process.

On December 18, 2020, DEA finalized [new regulations](#) pertaining to applications by entities seeking to become registered with DEA to grow marijuana as bulk manufacturers for research purposes. Under these and other applicable regulations, applicants are responsible for demonstrating they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion.

Kazmira Therapeutics: Transforming Vice into Virtue with Cannabis Rescheduling

(Watkins, CO – April 30, 2024) – Kazmira, a name synonymous with excellence and innovation in the cannabis industry, is proud to announce its strategic pivot towards a groundbreaking endeavor – Kazmira Therapeutics. This shift comes in the wake of a [proposal from the DEA moving to reschedule cannabis](#), marking a significant milestone in the industry and opening up new vistas for therapeutic applications of cannabis.

For years, Kazmira has been at the forefront of the cannabis sector, consistently establishing standards for quality, safety, and efficacy through its state-of-the-art facilities and strict adherence to current Good Manufacturing Practices (cGMP). Armed with cutting-edge proprietary technology, a highly skilled workforce, and robust infrastructure, Kazmira stands as a dominant force in the realm of cannabis therapeutics. These efforts have not only showcased Kazmira's commitment to excellence but have also laid a solid foundation for this transformative leap.

Cannabis Therapeutics are a Once in a Centennial Opportunity


The DEA's shift of cannabis from Schedule I to Schedule III will significantly broaden the spectrum of therapeutic possibilities. This change in scheduling seeks to balance the medicinal benefits of cannabis with the management of its potential for abuse, enabling the future of harm reduction therapies from cannabis.



Industrially-Zoned Areas



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT




Referral Comments

- Two letters in support
- Most “no comments”
- Centennial asked that we prohibit DEA facilities around Dove Valley/Inverness



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT



Planning Commission

- August 20, 2024 public hearing
- No public testimony
- Recommendation of approval
on a vote of 6-0 with no
modifications



ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT





ARAPAHOE COUNTY
PUBLIC WORKS & DEVELOPMENT

Questions?

